Joshua Resnick | Partner
SV Health Investors

Joshua Resnick, Partner, SV Health Investors

Josh co-leads SV’s US Biotech practice out of SV’s Boston office. He is also responsible for SV’s venture-creation activities, including the activities of SV’s incubator, Brahma Discovery. He is a member of the investment committee of the Dementia Discovery Fund. Josh is a highly-regarded life science venture capital leader, entrepreneur, and investment professional with more than 15 years of experience in investing, company formation, and company leadership across all stages from discovery through commercialization.
Prior experience
Before joining SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund that he built and managed within Merck & Co. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture, focusing on company formation, seed and Series A investing. During his tenure at Atlas, Josh was also the Founder and CEO of startups in the immune-oncology and neuro spaces. Prior to Atlas Venture, he was a Partner at Prism Venture Partners. Earlier, Josh founded or co-founded companies in the med tech and digital health spaces.
Academic credentials
BA, Magna Cum Laude, Chemistry, Williams College; MD, University of Pennsylvania School of Medicine; MBA, Wharton School of Business.
Outside of SV
Josh continues to practice medicine in an academic / teaching setting as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital and Brigham and Women’s Hospital. Josh is on the faculty of the Harvard Medical School (Emergency Medicine). Outside of work, Josh enjoys spending time with his children – and all manner of outdoor activities.


World Anti-Microbial Resistance Congress USA 2018 - Day 1 @ 11:30

VC Panel: Funding for innovative traditional drugs as well as non-traditional antibiotic development

  • Investing in traditional innovation in the antibiotic space
  • Non-traditional products and pipeline a private funders perspective.
  • What is the future of additional VC funding for both traditional and non-traditional antibiotics and innovation
last published: 21/Sep/18 19:05 GMT

back to speakers